,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2015-02-04 07:27:00,"BostonScientific Corporation ( BSX ) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 15 cents in the fourth quarter of 2014, 15.4% ahead of the year-ago adjusted number.",0.7969765067100525,0.09236441552639008,0.110659159719944,positive,0.7046120762825012
1,2015-02-04 07:27:00,"However, considering amortized expense adjustments, the quarter's adjusted EPS came in at 22 cents, 4.8% ahead of both the year-ago adjusted number and the Zacks Consensus Estimate.",0.5500452518463135,0.34442734718322754,0.10552740842103958,positive,0.20561790466308594
2,2015-02-04 07:27:00,The figure coincides with the upper end of the company's adjusted EPS guidance range of 20-22 cents.,0.05574408546090126,0.008118839003145695,0.9361370205879211,neutral,0.04762524738907814
3,2015-02-04 07:27:00,"Without these adjustments, the company reported net income of $87 million or EPS of 6 cents in the quarter, down from the year-ago net income of $108 million or EPS of 8 cents, respectively.",0.01667480170726776,0.9723349809646606,0.010990271344780922,negative,-0.9556601643562317
4,2015-02-04 07:27:00,"For full year 2014, Boston Scientific reported adjusted earnings (considering certain one-time adjustments including amortization expense) of 84 cents per share, reflecting a year-over-year improvement of 15.1%.",0.9545763731002808,0.027998074889183044,0.017425579950213432,positive,0.9265782833099365
5,2015-02-04 07:27:00,Full year EPS also beat the Zacks Consensus Estimate by a penny and exceeded the company's earlier projected band of 81-83 cents.,0.950135350227356,0.026383385062217712,0.02348131500184536,positive,0.923751950263977
6,2015-02-04 07:27:00,"Revenues in the fourth quarter registered a 2.7% increase year over year (7% growth at constant exchange rate or CER, excluding divested business) at $1.887 billion.",0.9558228254318237,0.01805843412876129,0.026118693873286247,positive,0.9377644062042236
7,2015-02-04 07:27:00,"The figure, although shy of the Zacks Consensus Estimate of $1.904 billion, remained within the company's guidance range of $1.875−$1.925 million.",0.6564117074012756,0.1382809281349182,0.20530733466148376,positive,0.5181307792663574
8,2015-02-04 07:27:00,"For full year 2014, the company reported revenues of $7.380 billion, up 3.3% year over year (operational revenue growth of 6%) and comfortably ahead of the Zacks Consensus Estimate of $2.305 billion.",0.9547683596611023,0.021762976422905922,0.023468662053346634,positive,0.9330053925514221
9,2015-02-04 07:27:00,The results were well within the company's guidance of $7.370-$7.420 billion.,0.7730385661125183,0.025787262246012688,0.20117413997650146,positive,0.7472513318061829
10,2015-02-04 07:27:00,"Boston Scientific currently has three global reportable segments comprising Cardiovascular, Rhythm Management and MedSurg.",0.020252270624041557,0.006100116763263941,0.9736475944519043,neutral,0.014152154326438904
11,2015-02-04 07:27:00,"The company generates maximum revenues from Cardiovascular, which comprises Interventional Cardiology and Peripheral Interventions.",0.028852129355072975,0.00474511319771409,0.9664027690887451,neutral,0.024107016623020172
12,2015-02-04 07:27:00,"Sales in these sub-segments were $523 million (up 10% year over year at CER) and $222 million (up 10%), respectively, during the fourth quarter.",0.9300666451454163,0.01648132875561714,0.0534520260989666,positive,0.9135853052139282
13,2015-02-04 07:27:00,"Global sales of coronary stent system (within Interventional Cardiology) were $303 million, up 5.6%.",0.9509394764900208,0.019303614273667336,0.029756875708699226,positive,0.931635856628418
14,2015-02-04 07:27:00,The improvement in drug-eluting stents (DES) performance that increased 6.9% to $291 million was partially offset by the poor bare-metal stents performance that plunged 20% to $12 million.,0.847642719745636,0.11907002329826355,0.03328731656074524,positive,0.7285727262496948
15,2015-02-04 07:27:00,"The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology.",0.10381655395030975,0.00600202102214098,0.8901814818382263,neutral,0.09781453013420105
16,2015-02-04 07:27:00,CRM reflected sales improvement of 3% to $468 million at CER.,0.9555805921554565,0.02756929025053978,0.016850139945745468,positive,0.9280112981796265
17,2015-02-04 07:27:00,"Worldwide sales from pacemakers (within CRM) dropped 4.4% to $129 million, while defibrillators increased 1.8% to $339 million.",0.01994502916932106,0.970973014831543,0.009081879630684853,negative,-0.9510279893875122
18,2015-02-04 07:27:00,Electrophysiology sales surged 23% year over year at CER to $59 million.,0.9564405083656311,0.022165467962622643,0.021393977105617523,positive,0.9342750310897827
19,2015-02-04 07:27:00,"Over the recent past, the company has been targeting vital product launches to revive the sales of the beleaguered Interventional Cardiology and CRM segments.",0.9054313898086548,0.012968702241778374,0.08159993588924408,positive,0.8924626708030701
20,2015-02-04 07:27:00,"The improved performance in these core segments in the reported quarter, proved beyond doubt that the measures undertaken are working effectively to counter the ongoing challenges.",0.9460527300834656,0.016139205545186996,0.037808019667863846,positive,0.9299135208129883
21,2015-02-04 07:27:00,"In the quarter, the improvement in Interventional Cardiology was driven by continued leadership of the Promus PREMIER Stent system in the U.S. and solid share gains in Japan.",0.9554293751716614,0.01733684353530407,0.027233771979808807,positive,0.9380925297737122
22,2015-02-04 07:27:00,"Other segments like Endoscopy, Urology/Women's Health and Neuromodulation (coming under the MedSurg broader group) recorded sales of $340 million (up 5% at CER), $140 million (up 9%) and $134 million (down 2%), respectively.",0.8022387623786926,0.03442656993865967,0.1633346527814865,positive,0.767812192440033
23,2015-02-04 07:27:00,Gross margin was up 57 basis points (bps) year over year to 70.4%.,0.9546805620193481,0.019423581659793854,0.025895806029438972,positive,0.9352569580078125
24,2015-02-04 07:27:00,Adjusted operating margin expanded 77 bps to 18.1% in the quarter.,0.9576113224029541,0.01784631237387657,0.02454238012433052,positive,0.9397650361061096
25,2015-02-04 07:27:00,"During the reported quarter, selling, general and administrative expenses increased 4% to $753 million while research and development expenses dropped 3.7% to $208 million.",0.7168116569519043,0.24432210624217987,0.03886628523468971,positive,0.47248953580856323
26,2015-02-04 07:27:00,Royalty expense increased 4.2% to $25 million.,0.9402228593826294,0.027076512575149536,0.03270065039396286,positive,0.9131463766098022
27,2015-02-04 07:27:00,"Boston Scientific exited the year with cash and cash equivalents of $587 million, a substantial 170.5% rise from $217 million at the end of fiscal 2013, and had long-term debt of $3.86 billion.",0.9395624399185181,0.018044088035821915,0.04239349067211151,positive,0.9215183258056641
28,2015-02-04 07:27:00,The company generated operating cash flow of $1.269 billion in 2014.,0.0762348547577858,0.00660494202747941,0.9171602129936218,neutral,0.06962991505861282
29,2015-02-04 07:27:00,"During the earnings call, Boston Scientific provided its full year 2015 guidance.",0.03352027013897896,0.013720414601266384,0.9527593851089478,neutral,0.01979985460639
30,2015-02-04 07:27:00,The company expects 2015 adjusted EPS (considering all one-time items including amortized expense) in the range of 88-92 cents.,0.03235093876719475,0.009191492572426796,0.9584576487541199,neutral,0.023159446194767952
31,2015-02-04 07:27:00,"The current Zacks Consensus Estimate stands at 90 cents, the midpoint of the guidance range.",0.05147797614336014,0.01591501198709011,0.9326069951057434,neutral,0.03556296229362488
32,2015-02-04 07:27:00,"Estimated revenues, on the other hand, are expected to remain in the range of $7.300-$7.500 billion (growth of 3% to 6% on an operational basis).",0.7635816931724548,0.015068618580698967,0.22134968638420105,positive,0.7485131025314331
33,2015-02-04 07:27:00,The current Zacks Consensus Estimate for revenues of $7.578 billion coincide with the company's outlook.,0.03205855190753937,0.006131686270236969,0.9618098139762878,neutral,0.0259268656373024
34,2015-02-04 07:27:00,"For the first quarter of 2015, adjusted earnings are expected in the band of 19-21 cents per share on revenues of $1.740−$1.800 billion.",0.062470272183418274,0.0137513792142272,0.9237784147262573,neutral,0.0487188920378685
35,2015-02-04 07:27:00,"The Zacks Consensus Estimate for EPS stands at 21 cents, while that for revenues is $1.831 billion.",0.017044665291905403,0.05318228900432587,0.9297730922698975,neutral,-0.03613762557506561
36,2015-02-04 07:27:00,"Amid challenging economic conditions, a competitive environment, and currency headwinds, Boston Scientific posted a mixed fourth-quarter 2014, beating our estimate on the earnings front while lagging the same with respect to revenues.",0.0386357456445694,0.9508746862411499,0.010489528998732567,negative,-0.9122389554977417
37,2015-02-04 07:27:00,"However, we are impressed that barring Neuromodulation, the company has managed to post an impressive performance with balanced growth across the rest of its segments.",0.9515369534492493,0.017393851652741432,0.031069107353687286,positive,0.9341431260108948
38,2015-02-04 07:27:00,"Moreover, the guidance for 2015 also helps us to rely on the sustainability of this growth performance.",0.6158216595649719,0.010985428467392921,0.3731929063796997,positive,0.6048362255096436
39,2015-02-04 07:27:00,"In 2014, Boston Scientific had strengthened its core businesses and invested in new technologies and global markets, which contributed to the solid results across its businesses and regions.",0.9546694755554199,0.016631685197353363,0.028698913753032684,positive,0.9380378127098083
40,2015-02-04 07:27:00,"Additionally, the company also showed an improvement in its margins and delivered double-digit adjusted EPS growth.",0.9567030668258667,0.020344281569123268,0.02295258641242981,positive,0.9363588094711304
41,2015-02-04 07:27:00,Boston scientific is currently looking forward to year 2015 wherein it expects to introduce more innovative medical technologies and solutions.,0.846731424331665,0.011782514862716198,0.1414860188961029,positive,0.8349488973617554
42,2015-02-04 07:27:00,"Boston Scientific has a strong pipeline of products under development, the launch of which should further drive the top line.",0.8635593056678772,0.0112874461337924,0.12515324354171753,positive,0.8522718548774719
43,2015-02-04 07:27:00,"We are, at the same time, encouraged by the focus on emerging markets, especially India and China.",0.6684192419052124,0.011948986910283566,0.3196317255496979,positive,0.6564702391624451
44,2015-02-04 07:27:00,"Currently, Boston Scientific retains a Zacks Rank #3 (Hold).",0.026575138792395592,0.010301409289240837,0.9631235003471375,neutral,0.016273729503154755
45,2015-02-04 07:27:00,"Some of the better-ranked Medical Product stocks are Abaxis, Inc. ( ABAX ), Cardiovascular Systems Inc. ( CSII ) and ICU Medical, Inc. ( ICUI ), all carrying a Zacks Rank #1 (Strong Buy).",0.827663779258728,0.030637305229902267,0.1416988968849182,positive,0.7970264554023743
46,2015-02-04 07:27:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
47,2015-02-04 07:27:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
48,2015-02-04 07:27:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
49,2015-02-04 07:27:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
